[go: up one dir, main page]

WO2001019851A3 - Opaminergic neuronal survival-promoting factors and uses thereof - Google Patents

Opaminergic neuronal survival-promoting factors and uses thereof Download PDF

Info

Publication number
WO2001019851A3
WO2001019851A3 PCT/CA2000/001049 CA0001049W WO0119851A3 WO 2001019851 A3 WO2001019851 A3 WO 2001019851A3 CA 0001049 W CA0001049 W CA 0001049W WO 0119851 A3 WO0119851 A3 WO 0119851A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
neuronal survival
opaminergic
promoting factors
rich protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2000/001049
Other languages
French (fr)
Other versions
WO2001019851A2 (en
Inventor
John Commissiong
Andrei A Raibekas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUROTROPHIC BIOSCIENCE Inc
Original Assignee
NEUROTROPHIC BIOSCIENCE Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEUROTROPHIC BIOSCIENCE Inc filed Critical NEUROTROPHIC BIOSCIENCE Inc
Priority to EP00960250A priority Critical patent/EP1220681A2/en
Priority to CA002383076A priority patent/CA2383076A1/en
Priority to JP2001523628A priority patent/JP2003511352A/en
Priority to AU72633/00A priority patent/AU7263300A/en
Priority to MXPA02002765A priority patent/MXPA02002765A/en
Publication of WO2001019851A2 publication Critical patent/WO2001019851A2/en
Publication of WO2001019851A3 publication Critical patent/WO2001019851A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention features a pharmaceutical composition that includes arginine-rich protein and a pharmaceutically-acceptable excipient. The invention also features methods for treatment of a neurodegenerative disease, methods for improving neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic arginine-rich protein's biological activity.
PCT/CA2000/001049 1999-09-16 2000-09-18 Opaminergic neuronal survival-promoting factors and uses thereof Ceased WO2001019851A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP00960250A EP1220681A2 (en) 1999-09-16 2000-09-18 Opaminergic neuronal survival-promoting factors and uses thereof
CA002383076A CA2383076A1 (en) 1999-09-16 2000-09-18 Dopaminergic neuronal survival-promoting factors and uses thereof
JP2001523628A JP2003511352A (en) 1999-09-16 2000-09-18 Dopaminergic neuron survival promoting factor and its use
AU72633/00A AU7263300A (en) 1999-09-16 2000-09-18 Opaminergic neuronal survival-promoting factors and uses thereof
MXPA02002765A MXPA02002765A (en) 1999-09-16 2000-09-18 Opaminergic neuronal survival promoting factors and uses thereof.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15466899P 1999-09-16 1999-09-16
US60/154,668 1999-09-16

Publications (2)

Publication Number Publication Date
WO2001019851A2 WO2001019851A2 (en) 2001-03-22
WO2001019851A3 true WO2001019851A3 (en) 2001-09-20

Family

ID=22552259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/001049 Ceased WO2001019851A2 (en) 1999-09-16 2000-09-18 Opaminergic neuronal survival-promoting factors and uses thereof

Country Status (6)

Country Link
EP (1) EP1220681A2 (en)
JP (1) JP2003511352A (en)
AU (1) AU7263300A (en)
CA (1) CA2383076A1 (en)
MX (1) MXPA02002765A (en)
WO (1) WO2001019851A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9115208B2 (en) 2001-03-20 2015-08-25 Amarantus Therapeutics, Inc. Dopaminergic neuronal survival-promoting factors and uses thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2403804A1 (en) * 2000-03-21 2001-09-27 Curagen Corporation Vegf-modulated genes and methods employing them
US7452969B2 (en) 2002-08-30 2008-11-18 Licentia Ltd Neurotrophic factor protein and uses thereof
EP1644406B1 (en) 2003-07-11 2012-08-15 DeveloGen Aktiengesellschaft Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
DK1969003T3 (en) 2005-12-14 2010-12-13 Hermo Pharma Ltd Applications of a neurotrophic factor protein
FI20080326A0 (en) * 2008-04-30 2008-04-30 Licentia Oy Neurotrophic factor MANF and its uses
GB0908934D0 (en) * 2009-05-26 2009-07-01 Univ The West Of Scotland Differentiation medium
EP3122370A1 (en) * 2014-03-28 2017-02-01 Buck Institute for Research on Aging Methods and compositions for modulating the immune system

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0327769A2 (en) * 1988-02-08 1989-08-16 FIDIA S.p.A. Novel neuronotrophic factor
WO1994010292A1 (en) * 1992-10-28 1994-05-11 Neurospheres Ltd. Biological factors and neural stem cells
US5438121A (en) * 1989-08-30 1995-08-01 Max-Planck-Gesellschaft zur Foderund der Wissenschaften e.V. Brain derived neurotrophic factor
WO1996033731A1 (en) * 1995-04-26 1996-10-31 Regeneron Pharmaceuticals, Inc. Methods of using neurotrophic factors to enhance neuronal grafts
WO1999014235A1 (en) * 1997-09-16 1999-03-25 Washington University Persephin and related growth factors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0327769A2 (en) * 1988-02-08 1989-08-16 FIDIA S.p.A. Novel neuronotrophic factor
US5438121A (en) * 1989-08-30 1995-08-01 Max-Planck-Gesellschaft zur Foderund der Wissenschaften e.V. Brain derived neurotrophic factor
WO1994010292A1 (en) * 1992-10-28 1994-05-11 Neurospheres Ltd. Biological factors and neural stem cells
WO1996033731A1 (en) * 1995-04-26 1996-10-31 Regeneron Pharmaceuticals, Inc. Methods of using neurotrophic factors to enhance neuronal grafts
WO1999014235A1 (en) * 1997-09-16 1999-03-25 Washington University Persephin and related growth factors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIN L -F H ET AL: "GDNF: A GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR FOR MIDBRAIN DOPAMINERGIC NEURONS", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, 1 May 1993 (1993-05-01), pages 1130 - 1132, XP000615244, ISSN: 0036-8075 *
PANCHISION D M ET AL: "AN IMMORTALIZED, TYPE-1 ASTROCYTE OF MESENCEPHALIC ORIGIN SOURCE OF A DOPAMINERGIC NEUROTROPHIC FACTOR", JOURNAL OF MOLECULAR NEUROSCIENCE,BIRKHAEUSER, CAMBRIDGE, MA,US, vol. 11, no. 3, December 1998 (1998-12-01), pages 209 - 221, XP000943928, ISSN: 0895-8696 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9115208B2 (en) 2001-03-20 2015-08-25 Amarantus Therapeutics, Inc. Dopaminergic neuronal survival-promoting factors and uses thereof

Also Published As

Publication number Publication date
WO2001019851A2 (en) 2001-03-22
MXPA02002765A (en) 2005-09-08
EP1220681A2 (en) 2002-07-10
AU7263300A (en) 2001-04-17
CA2383076A1 (en) 2001-03-22
JP2003511352A (en) 2003-03-25

Similar Documents

Publication Publication Date Title
IL207166A0 (en) Pharmaceutical compositions for treating amyloid diseases
WO2000063246A3 (en) Compounds and methods for modulating beta-catenin mediated gene expression
CA2367955A1 (en) Abc1 polypeptide and methods and reagents for modulating cholesterol levels
WO2000078344A8 (en) Prion protein peptides and uses thereof
AU1407399A (en) Treatment for alzheimer's disease
CA2222453A1 (en) Therapeutic and drug screening methods for the treatment and prevention of neuronal disease
EP0476044A4 (en) Treating disorders by application of insulin-like growth factors and analogs
MX9704030A (en) 2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof.
WO2002074956A3 (en) Dopaminergic neuronal survival-promoting factors and uses thereof
WO2003102016A3 (en) Amyloid peptide inactivating enzyme to treat alzheimer's disease
IL141507A0 (en) Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
AU6721998A (en) Therapeutic use of the smr1 protein and active derivatives thereof
WO2001019851A3 (en) Opaminergic neuronal survival-promoting factors and uses thereof
WO2002100836A3 (en) Compounds, compositions and methods for modulating beta-amyloid production
PH31643A (en) 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease.
AU4316600A (en) Human brain carboxypeptidase b
WO2003004517A3 (en) Peyers's patch and/or m-celle targeting ligands
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
AU1405899A (en) Treatment for alzheimer's disease
BR9811907A (en) Neisseria lactoferrin binding protein
AUPO089396A0 (en) Neuroactive peptide
WO2003097687A3 (en) Neuroprotective polypeptides and methods of use
WO1999050671A3 (en) Toso as a target for drug screening
AU2003202489A1 (en) Screening method
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2383076

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/002765

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 523628

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000960250

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000960250

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000960250

Country of ref document: EP